Is the detection of anti-hepatitis C virus core IgM influenced by the presence of serum rheumatoid factor?

J Med Virol

Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France.

Published: January 1995

Rheumatoid factor (RF) induces false-positive results in the detection of serum antibodies, especially of the IgM type. About 70% of the patients with chronic hepatitis C have abnormal levels of serum RF. The aim of this study was to determine whether the presence of serum RF could influence the detection of anti-HCV core IgM, using an assay designed not to pick up RFs by the addition of goat antibodies directed against human IgG in the sample diluent. Serum anti-HCV core IgM antibodies and RF were sought in 60 patients with chronic hepatitis C. Serum anti-HCV IgG antibodies and anti-HCV core IgM antibodies were also sought in 101 patients with high levels of RF. Anti-HCV core IgM antibodies were found in 45% and serum RF in 72% of the patients with chronic hepatitis C. Neither the prevalence nor the levels of RF differed significantly between IgM positive and negative patients. Eight percent of the 101 patients with raised RF had anti-HCV antibodies and two of them had anti-HCV core IgM antibodies. No patient without anti-HCV antibodies had anti-HCV core IgM antibodies. These results show that: a) the detection of anti-HCV core IgM in patients with chronic hepatitis C is independent of the presence of serum RF; b) high titers of serum RF are not responsible for false-positive results of anti-HCV IgM tests. The study suggests that the test used could be a confident tool for studies on the significance of anti-HCV core IgM antibodies in chronic hepatitis C.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmv.1890450113DOI Listing

Publication Analysis

Top Keywords

core igm
36
anti-hcv core
32
igm antibodies
24
chronic hepatitis
20
patients chronic
16
igm
12
presence serum
12
anti-hcv
12
antibodies anti-hcv
12
antibodies
11

Similar Publications

Due to their high developmental diversity and different regulatory and functional roles, B cell subpopulations can promote or inhibit tumor growth. An orthotopic murine HNSCC model was applied to investigate the B cell composition and function in HNSCCs. Using flow cytometry approaches, cells from the spleen, lymph nodes and tumors were analyzed.

View Article and Find Full Text PDF

Rationale: Chronic () airway infection is common and a key contributor to diminished lung function and early mortality in persons with cystic fibrosis (PwCF). Risk factors for chronic among PwCF include cystic fibrosis transmembrane conductance regulator genotype, genetic modifiers, and environmental factors. Intensive antibiotic therapy and highly effective modulators do not eradicate in most adolescents and adults with cystic fibrosis.

View Article and Find Full Text PDF

Background: SARS-CoV-2 transmission and COVID-19 disease severity is influenced by immunity from natural infection and/or vaccination. Population-level immunity is complicated by the emergence of viral variants. Antibody Fc-dependent effector functions are as important mediators in immunity.

View Article and Find Full Text PDF
Article Synopsis
  • - Polymeric IgM, an important immunoglobulin, has a strong ability to bind antigens and complements, primarily produced as hexamers or pentamers, with the latter containing a protein called the J-chain for enhanced transportation across cell layers.
  • - The study reveals that the J-chain competes with the sixth subunit during IgM assembly and exists in an unstructured form before stabilizing pentamer formation through interactions with newly formed structures.
  • - The process is regulated by a quality control factor known as ERp44, which ensures that only properly assembled IgM is secreted, thereby ensuring effective immune responses.
View Article and Find Full Text PDF

Peripheral neuropathy (PN) is a significant cause of morbidity associated with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of zanubrutinib with ibrutinib in patients with WM. This ad hoc analysis examined treatment outcomes with zanubrutinib or ibrutinib on PN symptoms associated with WM in patients enrolled in ASPEN.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!